Mechanism of Gamma Oscillation Synchronization in the Prefrontal-hippocampal Circuit for Memory Dysfunction in Patients With White Matter Lesions of Cerebral Small Vessel Disease
1 other identifier
observational
150
1 country
1
Brief Summary
The mechanism underlying memory impairment caused by white matter lesions of cerebral small vessel disease is still unclear. The disrupted synchronization of gamma oscillations in the prefrontal-hippocampal circuit is a potential key mechanism. Our study has demonstrated that white matter lesions lead to demyelination of the connection tracts between the prefrontal lobe and hippocampus, which is closely related to memory dysfunction. However, further studies are required to explore if these microstructural changes in white matter tracts influence memory function by affecting gamma oscillations. Thus, this project will use the previously established episodic memory task and event-related potential to determine the changes in gamma oscillations in the prefrontal-hippocampal circuit and the effects on memory encoding and retrieval. Combining multimodal imaging, we will explore the mediating role of white matter microstructure damage, and establish a machine learning prediction model for memory impairment. In addition, transcranial alternation current stimulation (tACS) will be used to investigate the mechanisms of memory improvement by regulating the prefrontal-hippocampal gamma oscillations. This project will clarify the neural oscillation mechanism underlying memory impairment caused by white matter lesions of cerebral small vessel disease, with the expectation of providing new predictive indicators and interventions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2024
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 7, 2024
CompletedFirst Submitted
Initial submission to the registry
May 20, 2025
CompletedFirst Posted
Study publicly available on registry
June 29, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
June 29, 2025
June 1, 2025
3.8 years
May 20, 2025
June 26, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Overall cognitive function
Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MOCA) scale scores.
baseline and one-year follow-up
Secondary Outcomes (5)
Attention and executive functions
Baseline and follow up
Language function
Baseline and one-year follow up
Memory function
Baseline and one-year follow up
Brain imaging data
baseline and one-year follow-up
Electroencephalogram (EEG) data.
baseline and one-year follow-up
Eligibility Criteria
Elderly population
You may qualify if:
- \- Individuals with cerebral small vessel disease, normal cognition or mild cognitive impairment subjects;
- Participants with complete demographic data, neuropsychiatric scale assessments, imaging data, and EEG data.
You may not qualify if:
- Severe aphasia, physical disability, or other conditions preventing completion of neuropsychological assessments;
- History of cerebrovascular stroke with documented neurological deficits during onset and corresponding lesions on neuroimaging;
- Neurological disorders that may cause cognitive impairment, including alcohol abuse, drug addiction, traumatic brain injury, epilepsy, encephalitis, or normal-pressure hydrocephalus;
- Systemic diseases potentially contributing to mild cognitive impairment (e.g., hepatic/renal insufficiency, endocrine disorders, vitamin deficiencies);
- Current diagnosis of major depressive disorder or psychiatric disorders.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, 100053, China
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 20, 2025
First Posted
June 29, 2025
Study Start
March 7, 2024
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
December 31, 2027
Last Updated
June 29, 2025
Record last verified: 2025-06